BiotechTube

Satralizumab

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Duchenne Muscular Dystrophy

Conditions

Duchenne Muscular Dystrophy

Trial Timeline

Apr 4, 2025 → Jun 30, 2028

NCT ID
NCT06450639

About Satralizumab

Satralizumab is a phase 2 stage product being developed by Roche for Duchenne Muscular Dystrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06450639. Target conditions include Duchenne Muscular Dystrophy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT05199688Phase 3Recruiting
NCT06450639Phase 2Recruiting

Competing Products

20 competing products in Duchenne Muscular Dystrophy

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
33
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
33
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
33
Tadalafil + PlaceboEli LillyPhase 3
77
DS-5141bDaiichi SankyoPhase 2
52
DS-5141bDaiichi SankyoPhase 1/2
41
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
41
NS-065/NCNP-01Nippon ShinyakuPhase 2
52
Viltolarsen + PlaceboNippon ShinyakuPhase 3
77
ViltolarsenNippon ShinyakuPhase 2
52
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
52
NS-065/NCNP-01Nippon ShinyakuPhase 1
33
NS-050/NCNP-03 + PlaceboNippon ShinyakuPhase 1/2
41
NS-089/NCNP-02Nippon ShinyakuPhase 2
52
ViltolarsenNippon ShinyakuPhase 3
77
NS-089/NCNP-02Nippon ShinyakuPhase 1/2
41
NS-065/NCNP-01 + PlaceboNippon ShinyakuPhase 2
52
ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wkMerckPhase 2
52
ACE-031 (Extension of cohort 1 from core study, A031-03) + ACE-031 (Extension of cohort 2 from core study, A031-03) + ACE-031 (Extension of cohort 3 from core study, A031-03)MerckPhase 2
52

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85